Medically reviewed by a licensed healthcare professional. Last updated March 2026.

Key Takeaways

  • Approximately 40-50% of commercial insurance plans now cover GLP-1 medications for weight loss, up from roughly 25% in 2023 [1].
  • Medicare does not cover GLP-1 medications for weight loss as of 2026, though bipartisan legislation is pending [2].
  • Only 13 states cover GLP-1 weight loss medications under Medicaid [1].
  • Prior authorization is required by most insurers and can take 1-4 weeks.
  • If denied, appeals are successful approximately 40-60% of the time with proper documentation.
  • Self-pay options start at $149/month for oral Wegovy and $299/month for Zepbound vials.

Current Insurance Landscape

Insurance coverage for GLP-1 weight loss medications has improved significantly over the past two years, driven by growing clinical evidence and employer demand. However, coverage remains inconsistent and navigating the process can be frustrating.

Commercial Insurance (Employer Plans)

The trend is moving toward coverage, but it depends heavily on your specific plan:

  • Large employers (5,000+ employees): Approximately 50-60% now cover at least one GLP-1 for weight loss [1]
  • Mid-size employers (500-5,000): Approximately 35-45% offer coverage
  • Small employers (under 500): Approximately 20-30% offer coverage
  • Individual marketplace plans (ACA): Coverage varies widely by state and plan tier

How to check your coverage: Call the number on the back of your insurance card and ask: "Does my plan cover Wegovy (semaglutide) or Zepbound (tirzepatide) for chronic weight management?" Ask for the specific prior authorization requirements and any step therapy requirements.

Medicare

Medicare Part D does not cover GLP-1 medications prescribed for weight loss as of 2026 [2]. Coverage is available for the diabetes indications:

  • Ozempic (semaglutide for type 2 diabetes) — Covered under Part D
  • Mounjaro (tirzepatide for type 2 diabetes) — Covered under Part D

The Treat and Reduce Obesity Act has bipartisan support in Congress and would expand Medicare Part D to cover FDA-approved anti-obesity medications. As of early 2026, this legislation has not passed [2].

If you're on Medicare: Discuss with your provider whether a diabetes indication applies. If you have type 2 diabetes, Ozempic or Mounjaro may be covered under your Part D benefit. Self-pay programs (NovoCare, LillyDirect) are also available regardless of insurance.

Medicaid

Coverage varies dramatically by state. As of 2026, only 13 states cover GLP-1 medications for obesity under their Medicaid programs [1]. Coverage is more common for diabetes indications.

Check your state's Medicaid formulary or call your Medicaid managed care plan to confirm coverage.

Prior Authorization: What to Expect

Nearly all insurance plans require prior authorization (PA) before covering GLP-1 weight loss medications. This means your provider must submit documentation proving medical necessity before the pharmacy can fill your prescription.

Common PA Requirements

Most insurers require documentation of some or all of the following:

  1. BMI documentation: Current height, weight, and calculated BMI meeting FDA thresholds (30+ or 27+ with comorbidity)
  2. Qualifying comorbidities: Diagnosis codes for weight-related conditions (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
  3. Prior weight loss attempts: Many insurers require 3-12 months of documented diet, exercise, or behavioral weight management attempts
  4. Lab work: Recent bloodwork including A1C, lipid panel, and metabolic panel
  5. Letter of medical necessity: A letter from your provider explaining why GLP-1 therapy is medically appropriate

Timeline

Step Typical Timeframe
Provider submits PA 1-3 business days
Insurance review 5-15 business days
Decision communicated 1-3 business days
Total 1-4 weeks

Step Therapy Requirements

Some plans require "step therapy" — trying and failing a less expensive medication before approving a GLP-1. Common step therapy requirements include:

  • 3-6 months of documented phentermine use
  • 3-6 months of documented orlistat (Alli/Xenical) use
  • Documented participation in a structured weight loss program

Your provider can often request a step therapy exception if they document medical reasons why the required medications are contraindicated or inappropriate.

What to Do If You're Denied

Step 1: Understand the Denial

Your insurer must provide a written denial with a specific reason. Common denial reasons include:

  • BMI does not meet plan threshold (some plans require BMI 35+ rather than the FDA threshold of 30+)
  • Insufficient documentation of prior weight loss attempts
  • Missing lab work or medical records
  • Plan exclusion for weight loss medications (no coverage at any criteria)

Step 2: Appeal

If denied, you have the right to appeal. Many denials are overturned on appeal — estimates suggest 40-60% success rates with proper documentation.

For your appeal, include:

  • Updated letter of medical necessity from your provider
  • Complete medical records documenting weight-related conditions
  • Documentation of all prior weight loss attempts with dates and outcomes
  • Relevant clinical trial evidence (STEP, SURMOUNT, SELECT trials)
  • Any additional lab work requested in the denial

Step 3: External Review

If your internal appeal is denied, you can request an external review by an independent third party. This is a right guaranteed under the ACA for most health plans. The external reviewer is not affiliated with your insurance company.

Step 4: Consider Alternatives

If all appeals fail, self-pay options have become significantly more affordable:

  • Oral Wegovy: $149-$299/month through select pharmacies
  • LillyDirect Zepbound: $299-$449/month for single-dose vials
  • NovoCare Wegovy injection: $499/month
  • Patient assistance programs: Free medication for qualifying low-income patients

Manufacturer Savings Programs

Even with insurance, out-of-pocket costs can be high. Manufacturer savings cards can reduce costs significantly:

Novo Nordisk (Wegovy)

  • Wegovy Savings Card: Eligible commercially insured patients may pay as little as $0-$25/month
  • NovoCare Patient Assistance Program: Free Wegovy for uninsured patients meeting income requirements (at or below 400% Federal Poverty Level)

Eli Lilly (Zepbound)

  • Zepbound Savings Card: Eligible commercially insured patients may save on monthly costs
  • Lilly Cares: Patient assistance for qualifying uninsured patients
  • LillyDirect: Self-pay pricing at $299-$449/month

Using HSA/FSA Funds

Prescription GLP-1 medications are eligible expenses under Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) when prescribed by a licensed provider. This effectively provides a tax discount of 20-35% depending on your tax bracket [3].

Pro tip: If your employer offers an HSA, you can use pre-tax dollars for GLP-1 medications regardless of whether your insurance covers them.

Getting Help

Navigating insurance coverage can be overwhelming. These resources can help:

  • Your provider's office (many have staff dedicated to prior authorizations)
  • Manufacturer patient support lines (NovoCare: 1-888-693-5262; Lilly: 1-800-545-6962)
  • Our GLP-1 clinic directory — many clinics assist with insurance navigation
  • Telehealth providers that handle insurance billing on your behalf

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.

Sources

  1. KFF. "Health Benefits Coverage of Weight Loss Drugs." 2024. https://www.kff.org/
  2. Kaiser Family Foundation. "Medicare Coverage of GLP-1 Drugs for Weight Loss." 2024.
  3. IRS. Publication 502: Medical and Dental Expenses. https://www.irs.gov/publications/p502